Lyell Immunopharma, Inc.(LYEL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LYEL Lyell Immunopharma, Inc.

交易中 03-24 10:24:09 EDT

19.56

+0.01

+0.05%

最高19.56	最低18.73	成交量1.62万
今开19.32	昨收19.55	日振幅4.27%
总市值4.56亿	流通市值2.77亿	总股本2,331万
成交额30.99万	换手率0.11%	流通股本1,416万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LYEL","market":"US","secType":"STK","nameCN":"Lyell Immunopharma, Inc.","latestPrice":19.56,"timestamp":1774362247013,"preClose":19.55,"halted":0,"volume":16159,"delay":0,"changeRate":0.0005115089514065479,"floatShares":14162100,"shares":23307143,"eps":-16.06,"marketStatus":"交易中","change":0.01,"latestTime":"03-24 10:24:09 EDT","open":19.32,"high":19.56,"low":18.725,"amount":309891.129262,"amplitude":0.042711,"askPrice":19.55,"askSize":18,"bidPrice":18.7,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-16.06,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1774382400000},"marketStatusCode":2,"adr":0,"listingDate":1623902400000,"exchange":"NASDAQ","adjPreClose":19.55,"preHourTrading":{"tag":"盘前","latestPrice":21.1,"preClose":19.55,"latestTime":"08:02 EDT","volume":6,"amount":126.60000000000001,"timestamp":1774353767908,"change":1.55,"changeRate":0.079284,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":19.55,"preClose":19.55,"latestTime":"16:10 EDT","volume":500,"amount":9775,"timestamp":1774296605200,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.127525,"impliedVol":0.6775,"impliedVolPercentile":0.48},"requestUrl":"/m/hq/s/LYEL","defaultTab":"news","newsList":[{"id":"1148869180","title":"Lyell Immunopharma任命Smital Shah为首席财务与商务官兼主要财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1148869180","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148869180?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:09","pubTimestamp":1773058151,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma, Inc.宣布任命Smital Shah担任首席财务与商务官及主要财务官职务。这一重要人事变动将进一步加强公司在财务战略与商业运营方面的领导力，为未来发展注入新的动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LYEL","BK4505","BK4139"],"gpt_icon":0},{"id":"1115827606","title":"Lyell Immunopharma完成额外5000万美元股权私募融资并任命Smital Shah为首席财务与业务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1115827606","media":"美股速递","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115827606?lang=zh_cn&edition=full","pubTime":"2026-03-09 20:02","pubTimestamp":1773057765,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma, Inc.（以下简称“Lyell Immunopharma”）近日宣布，公司已完成额外5000万美元的股权私募融资。与此同时，公司正式任命Smital Shah担任首席财务与业务官一职，负责统筹公司的财务与业务发展策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4539","BK4139","LYEL"],"gpt_icon":0},{"id":"1106628289","title":"Lyell Immunopharma启动首例头对头CAR-T细胞疗法3期临床试验，针对侵袭性大B细胞淋巴瘤患者开始给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1106628289","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106628289?lang=zh_cn&edition=full","pubTime":"2026-02-12 20:31","pubTimestamp":1770899474,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma, Inc.（简称Lyell）宣布，在一项开创性的3期临床试验中，已开始对侵袭性大B细胞淋巴瘤患者进行给药。该试验采用头对头比较设计，是同类CAR-T细胞疗法中的首例研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4505","LYEL","BK4139"],"gpt_icon":0},{"id":"2610959478","title":"Lyell Immunopharma, Inc.盘中异动 早盘大幅下跌5.19%报22.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610959478","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610959478?lang=zh_cn&edition=full","pubTime":"2026-02-11 22:58","pubTimestamp":1770821896,"startTime":"0","endTime":"0","summary":"北京时间2026年02月11日22时58分，Lyell Immunopharma, Inc.股票出现异动，股价大幅跳水5.19%。截至发稿，该股报22.48美元/股，成交量6036股，换手率0.03%，振幅3.23%。Lyell Immunopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.91%。其相关个股中，Quince Therapeutics, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Phio Pharmaceuticals Corp.涨幅较大，Pmgc Holdings Inc.、Quince Therapeutics, Inc.、Aspire Biopharma Holdings, Inc.较为活跃，换手率分别为1964.18%、322.57%、180.28%，振幅较大的相关个股有Quince Therapeutics, Inc.、Tuhura Biosciences, Inc.、Biorestorative Therapies, Inc.，振幅分别为27.25%、23.08%、21.76%。Lyell Immunopharma, Inc.公司简介：Lyell Immunopharma Inc 是一家临床阶段的细胞治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021122581797a5d337&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021122581797a5d337&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","LYEL","BK4539"],"gpt_icon":0},{"id":"2595723519","title":"Lyell Immunopharma, Inc.盘中异动 股价大跌5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595723519","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595723519?lang=zh_cn&edition=full","pubTime":"2025-12-30 23:20","pubTimestamp":1767108023,"startTime":"0","endTime":"0","summary":"北京时间2025年12月30日23时20分，Lyell Immunopharma, Inc.股票出现波动，股价快速下跌5.13%。Lyell Immunopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.74%。其相关个股中，Cdt Equity Inc C/Wts 22/09/2028、Dermata Therapeutics, Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 涨幅较大，Dermata Therapeutics, Inc.、Gri Bio, Inc.、Theriva Biologics, Inc.较为活跃，换手率分别为1745.05%、611.82%、38.17%，振幅较大的相关个股有Briacell Therapeutics Corp C/Wts 26/02/2026、Protagenic Therapeutics Inc C/Wts 26/04/2026 、Tevogen Bio Holdings Inc C/Wts 14/02/2029 ，振幅分别为37.47%、37.42%、30.29%。Lyell Immunopharma, Inc.公司简介：Lyell Immunopharma Inc 是一家临床阶段的细胞治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230232023a48ae223&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230232023a48ae223&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LYEL","BK4539","BK4505"],"gpt_icon":0},{"id":"1151565275","title":"Lyell Immunopharma, Inc.：H.C. Wainwright调高评级至买入，并将目标价上调至45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1151565275","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151565275?lang=zh_cn&edition=full","pubTime":"2025-12-09 19:17","pubTimestamp":1765279051,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma, Inc.：H.C. Wainwright调高评级至买入，并将目标价上调至45美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","LYEL","BK4539"],"gpt_icon":0},{"id":"1190850669","title":"Lyell Immunopharma 在第67届 ASH 年会中展示 Ronde-Cel 正在进行的试验新临床数据，显示大B细胞淋巴瘤患者中具有高比例的持久完全缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1190850669","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190850669?lang=zh_cn&edition=full","pubTime":"2025-12-08 05:32","pubTimestamp":1765143129,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma 在第67届 ASH 年会中展示 Ronde-Cel 正在进行的试验新临床数据，显示大B细胞淋巴瘤患者中具有高比例的持久完全缓解","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LYEL","BK4539","BK4139","BK4505"],"gpt_icon":0},{"id":"1166898982","title":"Lyell Immunopharma拟申请Innovative Cellular Therapeutics Holdings Limited不定期转售最多190万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1166898982","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166898982?lang=zh_cn&edition=full","pubTime":"2025-12-06 05:40","pubTimestamp":1764970814,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma拟申请Innovative Cellular Therapeutics Holdings Limited不定期转售最多190万股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","LYEL","BK4139","BK4539"],"gpt_icon":0},{"id":"2582345927","title":"Lyell Immunopharma, Inc.盘中异动 快速下挫8.99%报16.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582345927","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582345927?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:30","pubTimestamp":1762871439,"startTime":"0","endTime":"0","summary":"北京时间2025年11月11日22时30分，Lyell Immunopharma, Inc.股票出现波动，股价大幅下挫8.99%。截至发稿，该股报16.09美元/股，成交量832股，换手率0.00%，振幅4.92%。Lyell Immunopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Quoin Pharmaceuticals Ltd、Engene Holdings Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Quoin Pharmaceuticals Ltd、Aspire Biopharma Holdings, Inc.、Galecto, Inc.较为活跃，换手率分别为1495.39%、258.01%、108.57%，振幅较大的相关个股有Quoin Pharmaceuticals Ltd、Lyell Immunopharma, Inc.、Inflarx N.V.，振幅分别为14.13%、9.67%、7.59%。Lyell Immunopharma, Inc.公司简介：Lyell Immunopharma Inc 是一家临床阶段的细胞治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111223039a49a1717&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111223039a49a1717&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4505","BK4139","LYEL"],"gpt_icon":0},{"id":"1177259320","title":"Lyell Immunopharma：根据协议，额外现金对价包括高达6.75亿美元的商业销售里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1177259320","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177259320?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:37","pubTimestamp":1762778235,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma：根据协议，额外现金对价包括高达6.75亿美元的商业销售里程碑","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LYEL","BK4505","BK4539","BK4139"],"gpt_icon":0},{"id":"1110997827","title":"Lyell Immunopharma：根据协议，额外现金考虑包括3000万美元的临床里程碑和最高1.15亿美元的晚期监管里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1110997827","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110997827?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:37","pubTimestamp":1762778232,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma：根据协议，额外现金考虑包括3000万美元的临床里程碑和最高1.15亿美元的晚期监管里程碑","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LYEL","BK4539","BK4505"],"gpt_icon":0},{"id":"1146784437","title":"Lyell Immunopharma, Inc.预计2025年净现金使用将在1.55亿至1.6亿美元之间，不包括交易中4000万美元的预付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1146784437","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146784437?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:32","pubTimestamp":1762777945,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma, Inc.预计2025年净现金使用将在1.55亿至1.6亿美元之间，不包括交易中4000万美元的预付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4539","LYEL","BK4139"],"gpt_icon":0},{"id":"1165630662","title":"Lyell Immunopharma获得用于转移性结直肠癌临床开发的下一代CAR T细胞产品候选药物的全球独家权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1165630662","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165630662?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:32","pubTimestamp":1762777934,"startTime":"0","endTime":"0","summary":"Lyell Immunopharma获得用于转移性结直肠癌临床开发的下一代CAR T细胞产品候选药物的全球独家权利","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","LYEL","BK4539"],"gpt_icon":0},{"id":"1138858571","title":"Lyell在第67届ASH年会及博览会上宣布Ronde-Cel治疗侵袭性大B细胞淋巴瘤的1/2期临床试验的两项口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1138858571","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138858571?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:01","pubTimestamp":1762178507,"startTime":"0","endTime":"0","summary":"Lyell在第67届ASH年会及博览会上宣布Ronde-Cel治疗侵袭性大B细胞淋巴瘤的1/2期临床试验的两项口头报告","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4539","LYEL","BK4139"],"gpt_icon":0},{"id":"2577302944","title":"Lyell Immunopharma, Inc.盘中异动 急速下挫6.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577302944","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577302944?lang=zh_cn&edition=full","pubTime":"2025-10-22 22:47","pubTimestamp":1761144463,"startTime":"0","endTime":"0","summary":"北京时间2025年10月22日22时47分，Lyell Immunopharma, Inc.股票出现波动，股价快速下挫6.35%。Lyell Immunopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.37%。其相关个股中，Adaptimmune Therapeutics Plc、Cero Therapeutics Holdings Inc C/Wts 14/02/2029 、Engene Holdings Inc C/Wts 31/10/2028  Cl A涨幅较大，Adaptimmune Therapeutics Plc、Rani Therapeutics Holdings, Inc.、Minerva Neurosciences, Inc较为活跃，换手率分别为85.90%、80.75%、31.63%，振幅较大的相关个股有Adaptimmune Therapeutics Plc、Apollomics Inc C/Wts 01/04/2028 、Rani Therapeutics Holdings, Inc.，振幅分别为73.25%、29.17%、28.77%。Lyell Immunopharma, Inc.公司简介：Lyell Immunopharma Inc 是一家临床阶段的细胞治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102222474394d7f6d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102222474394d7f6d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LYEL","BK4539","BK4505"],"gpt_icon":0},{"id":"2570880555","title":"Lyell Immunopharma, Inc.盘中异动 临近收盘大幅下跌5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570880555","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570880555?lang=zh_cn&edition=full","pubTime":"2025-09-26 03:50","pubTimestamp":1758829857,"startTime":"0","endTime":"0","summary":"北京时间2025年09月26日03时50分，Lyell Immunopharma, Inc.股票出现异动，股价快速下跌5.13%。截至发稿，该股报12.76美元/股，成交量2.4865万股，换手率0.13%，振幅3.05%。Lyell Immunopharma, Inc.股票所在的生物技术行业中，整体跌幅为1.15%。其相关个股中，Pepgen Inc.、Scisparc Ltd.、Briacell Therapeutics Corp C/Wts 26/02/2026涨幅较大，Scisparc Ltd.、Evaxion A/S、Qualigen Therapeutics, Inc.较为活跃，换手率分别为5443.80%、1207.91%、739.13%，振幅较大的相关个股有Scisparc Ltd.、Geovax Labs Inc C/Wts 29/09/2025、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为95.30%、86.27%、58.88%。Lyell Immunopharma, Inc.公司简介：Lyell Immunopharma Inc 是一家临床阶段的细胞治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926035058a4441c24&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926035058a4441c24&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4539","LYEL","BK4139"],"gpt_icon":0},{"id":"2518276241","title":"Lyell Immunopharma, Inc.盘中异动 股价大跌5.50%报0.702美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518276241","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518276241?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:08","pubTimestamp":1741615693,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时08分，Lyell Immunopharma, Inc.股票出现波动，股价急速下跌5.50%。截至发稿，该股报0.702美元/股，成交量1.5766万股，换手率0.01%，振幅2.49%。Lyell Immunopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3198.22%、693.41%、99.01%，振幅较大的相关个股有Scisparc Ltd.、Pmgc Holdings Inc.、Impact Biomedical, Inc.，振幅分别为40.24%、32.14%、28.59%。Lyell Immunopharma, Inc.公司简介：Lyell Immunopharma Inc 是一家临床阶段的细胞治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022081396403f35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022081396403f35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","LYEL","BK4505"],"gpt_icon":0},{"id":"2517600808","title":"Lyell Immunopharma, Inc.盘中异动 下午盘快速拉升5.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517600808","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517600808?lang=zh_cn&edition=full","pubTime":"2025-03-05 02:39","pubTimestamp":1741113562,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日02时39分，Lyell Immunopharma, Inc.股票出现波动，股价大幅拉升5.82%。Lyell Immunopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.44%。其相关个股中，Protagenic Therapeutics Inc C/Wts 29/04/2026 、Immatics N V C/Wts 01/07/2025 、Protagenic Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1287.72%、1183.09%、1142.85%，振幅较大的相关个股有Cyclacel Pharmaceuticals Inc 6% Cnv Pfd Usd、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Celularity Inc C/Wts 16/07/2026 ，振幅分别为122.48%、66.67%、66.02%。Lyell Immunopharma, Inc.公司简介：Lyell Immunopharma Inc 是一家临床阶段的细胞治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305023923989be6d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305023923989be6d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","LYEL","BK4539"],"gpt_icon":0},{"id":"2516634275","title":"Lyell Immunopharma, Inc.盘中异动 股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634275","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516634275?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:31","pubTimestamp":1741012319,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时31分，Lyell Immunopharma, Inc.股票出现异动，股价急速下挫5.04%。截至发稿，该股报0.675美元/股，成交量1.0313万股，换手率0.00%，振幅2.81%。Lyell Immunopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Entero Therapeutics Inc.、Alto Neuroscience, Inc.、Geovax Labs, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为47.20%、24.20%、22.45%，振幅较大的相关个股有Entero Therapeutics Inc.、Cibus, Inc.、Galmed Pharmaceuticals Ltd.，振幅分别为15.16%、9.55%、9.35%。Lyell Immunopharma, Inc.公司简介：Lyell Immunopharma Inc 是一家临床阶段的细胞治疗公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223200abe63343&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223200abe63343&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LYEL","BK4139","BK4539","BK4505"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lyell.com","stockEarnings":[{"period":"1week","weight":-0.0748},{"period":"1month","weight":-0.0864},{"period":"3month","weight":-0.4763},{"period":"6month","weight":0.4535},{"period":"1year","weight":0.6897},{"period":"ytd","weight":-0.3648}],"compareEarnings":[{"period":"1week","weight":-0.0204},{"period":"1month","weight":-0.0494},{"period":"3month","weight":-0.0474},{"period":"6month","weight":-0.0087},{"period":"1year","weight":0.1621},{"period":"ytd","weight":-0.0389}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Lyell Immunopharma, Inc.于2018年6月29日在特拉华州注册成立。该公司是一家后期临床细胞治疗公司，正在为癌症患者推进专有的下一代自体嵌合抗原受体（CAR）T细胞候选产品。该公司的目标是充分实现细胞疗法对血液系统恶性肿瘤和实体瘤患者的治疗潜力。为了实现这一目标，该公司正在开拓旨在产生T细胞疗法的新方法，以推动持久的临床反应。该公司的CAR T细胞候选产品从确定有前景的癌症靶点开始。然后，该公司设计患者自己的活免疫细胞，并为其提供创新的增强功能，包括CAR构建、技术和制造方案，旨在赋予T细胞更强大的癌症细胞杀伤能力。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.135683},{"month":2,"riseRate":0.6,"avgChangeRate":0.14638},{"month":3,"riseRate":0.2,"avgChangeRate":-0.173927},{"month":4,"riseRate":0.25,"avgChangeRate":-0.066906},{"month":5,"riseRate":0.5,"avgChangeRate":0.143482},{"month":6,"riseRate":0.5,"avgChangeRate":0.026837},{"month":7,"riseRate":0.4,"avgChangeRate":0.020455},{"month":8,"riseRate":0.4,"avgChangeRate":-0.008473},{"month":9,"riseRate":0.4,"avgChangeRate":0.012765},{"month":10,"riseRate":0.4,"avgChangeRate":-0.081669},{"month":11,"riseRate":0.4,"avgChangeRate":-0.025774},{"month":12,"riseRate":0.4,"avgChangeRate":-0.056847}],"exchange":"NASDAQ","name":"Lyell Immunopharma, Inc.","nameEN":"Lyell Immunopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lyell Immunopharma, Inc.(LYEL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Lyell Immunopharma, Inc.(LYEL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Lyell Immunopharma, Inc.,LYEL,Lyell Immunopharma, Inc.股票,Lyell Immunopharma, Inc.股票老虎,Lyell Immunopharma, Inc.股票老虎国际,Lyell Immunopharma, Inc.行情,Lyell Immunopharma, Inc.股票行情,Lyell Immunopharma, Inc.股价,Lyell Immunopharma, Inc.股市,Lyell Immunopharma, Inc.股票价格,Lyell Immunopharma, Inc.股票交易,Lyell Immunopharma, Inc.股票购买,Lyell Immunopharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lyell Immunopharma, Inc.(LYEL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Lyell Immunopharma, Inc.(LYEL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}